Skip to content
  • Home
  • Background
    • Science & Clinical
  • Platform
    • Biological Plausibility
    • Target Overview: Market
    • Target Overview : Tissue Target
  • Hypo-Stream Logo Hypo-Stream Logo
  • Burns
    • Headlines
    • Survival Impact of M3
    • Survival Curve Analysis
    • Antimicrobial Action
  • Founders
    • Founding Advisory Team
    • Additional Advisors
  • Contact

8. Burns clinical trial offers opportunity to expand label with Ph IV data (surgical site, inhalation burns)

7. Patent protected in USA, EU, Japan

6. Antimicrobial action against AMR species

5. Unique anti-inflammatory action without compromising immunocompetence

4. M3 – Anti-Il-6 action reverses cytokine storm / AIRS / Septic shock

3. Regulator advice confirms Ph III ready (study duration 12 month, n150 study)- Orphan designated in EU.

2. Odds ratio 0.19 showing 5x chance of survival

1. Doubled survival in high-mortality ICU specialty severe burns (32% to 66% - p= 0.007)

Hypo-Stream | Burns: Headlinesluke2019-04-30T12:33:24+01:00
© Copyright Hypo-Stream ( ~ onward)   |   Website by Luke Hall Web Design   |   All Rights Reserved
This website uses cookies and third party services. No personal data is gathered or stored. To consent to the use of cookies, please click to confirm. Consent
Go to Top